(Mark One) | |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||
300 East Lombard Street, Suite 1710 | ||||||
(Zip Code) | ||||||
(Address of principal executive office (US)) | ||||||
(Registrant's telephone number, including area code) | ||||||
Securities registered pursuant to section 12(b) of the Act | ||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
☑ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ||
Emerging growth company |
Page | |||
Item 1. | |||
Item 2. | |||
Item 3. | |||
Item 4. | |||
Item 1. | |||
Item 1A. | |||
Item 2. | |||
Item 3. | |||
Item 4. | |||
Item 5. | |||
Item 6. | |||
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Revenue | 2 | |||||||||
Cost of sales (excluding depreciation and amortization) | ( | ( | ( | ( | ||||||
Depreciation and amortization | ( | ( | ( | ( | ||||||
Selling and administrative expenses | ( | ( | ( | ( | ||||||
Research and development expenses | ( | ( | ( | ( | ||||||
Other gains and losses – net | 4 | ( | ||||||||
Finance costs – net | 5 | ( | ( | ( | ( | |||||
Income before tax | ||||||||||
Income tax expense | 6 | ( | ( | ( | ( | |||||
Net income | ||||||||||
Attributable to: | ||||||||||
Equity holders of Constellium SE | ||||||||||
Non-controlling interests | ||||||||||
Net income | ||||||||||
Earnings per share attributable to the equity holders of Constellium SE (in U.S. dollars) | Notes | |||||||||
Basic | 7 | |||||||||
Diluted | 7 |
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Net income | ||||||||||
Other comprehensive (loss) / income | ||||||||||
Net change in post-employment benefit obligations | ( | ( | ( | ( | ||||||
Income tax on net change in post- employment benefit obligations | ||||||||||
Net change in cash flow hedges | 12 | ( | ( | ( | ||||||
Income tax on cash flow hedges | ( | |||||||||
Currency translation adjustments | ( | ( | ||||||||
Other comprehensive (loss) / income | ( | ( | ( | |||||||
Total comprehensive income | ||||||||||
Attributable to: | ||||||||||
Equity holders of Constellium SE | ||||||||||
Non-controlling interests | ||||||||||
Total comprehensive income | ||||||||||
(in millions of U.S. dollars) except share data and as otherwise stated | Notes | At September 30, 2026 | At December 31, 2025 | |||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
Trade receivables and other, net | 8 | |||||
Inventories | 9 | |||||
Fair value of derivative instruments and other financial assets | 12 | |||||
Total current assets | ||||||
Non-current assets | ||||||
Property, plant and equipment, net | ||||||
Goodwill | ||||||
Intangible assets, net | ||||||
Deferred tax assets | ||||||
Trade receivables and other, net | 8 | |||||
Fair value of derivative instruments | 12 | |||||
Total non-current assets | ||||||
Total assets | ||||||
Liabilities | ||||||
Current liabilities | ||||||
Trade payables and other | 10 | |||||
Current portion of long-term debt | 11 | |||||
Fair value of derivative instruments | 12 | |||||
Income tax payable | ||||||
Pension and other benefit obligations | ||||||
Provisions | 14 | |||||
Total current liabilities | ||||||
Non-current liabilities | ||||||
Trade payables and other | 10 | |||||
Long-term debt | 11 | |||||
Fair value of derivative instruments | 12 | |||||
Pension and other benefit obligations | ||||||
Provisions | 14 | |||||
Deferred tax liabilities | ||||||
Total non-current liabilities | ||||||
Total liabilities | ||||||
Commitments and contingencies | 14 | |||||
Shareholders' equity | ||||||
Ordinary shares, par value € September 30, 2026 and at December 31, 2025, respectively; respectively | ||||||
Additional paid in capital | ||||||
Accumulated other comprehensive income | 15 | |||||
Retained earnings | ||||||
Treasury shares 2025 | ( | ( | ||||
Equity attributable to equity holders of Constellium SE | ||||||
Non-controlling interests | ||||||
Total equity | ||||||
Total equity and liabilities |
in millions of U.S. dollars, except share amounts | Ordinary shares outstanding | Ordinary shares | Treasury shares | Accumulated other comprehensive income / (loss) | Additional paid in capital | Retained earnings | Non- controlling interests | Total equity | ||||||||
At January 1, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | ( | ||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive income | — | — | — | ( | — | ( | ||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | ( | — | |||||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At March 31, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive income | — | — | — | ( | — | |||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Other | — | — | — | — | ( | ( | ( | |||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At June 30, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive (loss) / income | — | — | — | ( | — | |||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | — | — | — | ||||||||||
Cancellation of treasury shares | — | — | — | ( | — | — | ( | |||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At September 30, 2026 | ( | |||||||||||||||
in millions of U.S. dollars, except share amounts | Ordinary shares outstanding | Ordinary shares | Treasury shares | Accumulated other comprehensive income / (loss) | Additional paid in capital | Retained earnings | Non- controlling interests | Total equity | ||||||||
At January 1, 2025 | ( | ( | ||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive loss | — | — | — | — | — | — | ||||||||||
Total comprehensive (loss) / income | — | — | — | — | ||||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | ( | — | |||||||||||
Other | — | — | — | — | ( | — | ||||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At March 31, 2025 | ( | ( | ||||||||||||||
Net income | — | — | — | — | — | — | ||||||||||
Other comprehensive loss | — | — | — | — | — | |||||||||||
Total comprehensive (loss) / income | — | — | — | — | ||||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At June 30, 2025 | ( | |||||||||||||||
Net income | — | — | — | — | — | — | ||||||||||
Other comprehensive income | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive income | — | — | — | ( | — | |||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At September 30, 2025 | ( |
Nine months ended September 30, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Net income | ||||||
Adjustments | ||||||
Depreciation and amortization | 3 | |||||
Impairment of assets | 3 | |||||
Pension and other long-term benefits | ||||||
Finance costs - net | 5 | |||||
Income tax expense | ||||||
Unrealized (gains) /losses on derivatives - net and from remeasurement of monetary assets and liabilities - net | ( | |||||
Losses on disposal | 4 | |||||
Other - net | ||||||
Changes in working capital | ||||||
Inventories | ( | ( | ||||
Trade receivables | ( | ( | ||||
Trade payables | ||||||
Other | ( | |||||
Change in provisions | ( | ( | ||||
Pension and other long-term benefits paid | ( | ( | ||||
Interest paid | ( | ( | ||||
Income tax paid | ( | ( | ||||
Net cash flows from operating activities | ||||||
Purchases of property, plant and equipment | 3 | ( | ( | |||
Property, plant and equipment inflows | 3 | |||||
Collection of deferred purchase price receivable | 8 | |||||
Proceeds from disposals, net of cash | ||||||
Other investing activities | ||||||
Net cash flows used in investing activities | ( | ( | ||||
Repurchase of ordinary shares | ( | ( | ||||
Repayments of long-term debt | ( | ( | ||||
Net change in revolving credit facilities and short-term debt | ||||||
Finance lease repayments | ( | ( | ||||
Transactions with non-controlling interests | ( | ( | ||||
Other financing activities | ( | |||||
Net cash flows used in financing activities | ( | ( | ||||
Net (decrease) / increase in cash and cash equivalents | ( | |||||
Cash and cash equivalents - beginning of period | ||||||
Net (decrease) / increase in cash and cash equivalents | ( | |||||
Effect of exchange rate changes on cash and cash equivalents | ( | |||||
Cash and cash equivalents - end of period | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Aerospace rolled products | ||||||||
Transportation, industry, defense and other rolled products | ||||||||
Packaging rolled products | ||||||||
Automotive rolled products | ||||||||
Specialty and other thin-rolled products | ||||||||
Automotive extruded products | ||||||||
Other extruded products | ||||||||
Total revenue | ||||||||
Three months ended September 30, | ||||||||||
2026 | 2025 | |||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | H&C (B) | A&T | P&ARP | AS&I | H&C (B) | ||
Segment revenue | ||||||||||
Inter-segment elimination | ( | ( | ( | ( | ( | ( | ||||
External revenue | ||||||||||
Cost of metal | ( | ( | ( | ( | ( | ( | ||||
Production costs | ( | ( | ( | ( | ( | ( | ( | ( | ||
Other segment expenses (A) | ( | ( | ( | ( | ( | ( | ( | ( | ||
Segment Adjusted EBITDA | ( | ( | ||||||||
Nine months ended September 30, | ||||||||||
2026 | 2025 | |||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | H&C (B) | A&T | P&ARP | AS&I | H&C (B) | ||
Segment revenue | ||||||||||
Inter-segment elimination | ( | ( | ( | ( | ( | ( | ||||
External revenue | ||||||||||
Cost of metal | ( | ( | ( | ( | ( | ( | ||||
Production costs | ( | ( | ( | ( | ( | ( | ( | ( | ||
Other segment expenses (A) | ( | ( | ( | ( | ( | ( | ( | ( | ||
Segment Adjusted EBITDA | ( | ( | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
A&T | ||||||||||
P&ARP | ||||||||||
AS&I | ||||||||||
H&C (A) | ( | ( | ( | ( | ||||||
Segment Adjusted EBITDA | ||||||||||
Metal price lag (B) | ( | |||||||||
Depreciation and amortization | ( | ( | ( | ( | ||||||
Impairment of assets | ( | |||||||||
Share based compensation | 16 | ( | ( | ( | ( | |||||
Pension and other post-employment benefits - non-operating gains | ||||||||||
Restructuring costs | ( | ( | ( | |||||||
Unrealized (losses) / gains on derivatives | ( | |||||||||
Unrealized exchange gains / (losses) from the remeasurement of monetary assets and liabilities – net | ||||||||||
Losses on disposal | ( | ( | ||||||||
Other (C) | ( | ( | ( | |||||||
Expenses on factoring arrangements | 8 | ( | ( | ( | ( | |||||
Finance costs – net | 5 | ( | ( | ( | ( | |||||
Income before tax | ||||||||||
Income tax expense | 6 | ( | ( | ( | ( | |||||
Net income | ||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
A&T | ( | ( | ( | ( | ||||
P&ARP | ( | ( | ( | ( | ||||
AS&I | ( | ( | ( | ( | ||||
H&C (A) | ( | ( | ( | ( | ||||
Total capital expenditures (B) | ( | ( | ( | ( | ||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
A&T | ( | ( | ( | ( | ||||
P&ARP | ( | ( | ( | ( | ||||
AS&I | ( | ( | ( | ( | ||||
H&C (A) | ( | ( | ( | ( | ||||
Total depreciation, amortization and impairment expense | ( | ( | ( | ( | ||||
(in millions of U.S. dollars) | At September 30, 2026 | At December 31, 2025 | ||
A&T | ||||
P&ARP | ||||
AS&I | ||||
H&C (A) | ||||
Deferred income tax assets | ||||
Cash and cash equivalents | ||||
Fair value of derivative instruments and other financial assets | ||||
Total assets |
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Operating income and expenses | ||||||||||
Realized gains / (losses) on derivatives (A) | ( | ( | ||||||||
Unrealized (losses) / gains on derivatives at fair value through profit and loss - net (A) | 12 | ( | ||||||||
Unrealized exchange gains / (losses) from the remeasurement of monetary assets and liabilities – net | ||||||||||
Impairment of assets | ( | |||||||||
Restructuring costs | ( | ( | ( | |||||||
Losses on disposal | ( | ( | ||||||||
Result from the flood in Valais | 3 | |||||||||
Non-operating income and expenses | ||||||||||
Expenses on factoring arrangements | 8 | ( | ( | ( | ( | |||||
Pension and other post-employment benefits | 13 | |||||||||
Other | ( | ( | ( | |||||||
Total other gains and losses - net | ( | |||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Interest expense on borrowings (A) | ( | ( | ( | ( | ||||||
Interest expense on finance leases | ( | ( | ||||||||
Interest cost on pension and other long-term benefits | 13 | ( | ( | ( | ( | |||||
Net loss on settlement of debt | ( | ( | ||||||||
Realized and unrealized (losses) / gains on debt derivatives at fair value (B) | 12 | ( | ||||||||
Realized and unrealized exchange gains / (losses) on financing activities - net (B) | ||||||||||
Other finance expenses | ( | ( | ( | ( | ||||||
Capitalized borrowing costs (C) | ||||||||||
Finance expenses | ( | ( | ( | ( | ||||||
Finance costs - net | ( | ( | ( | ( | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars except share and per share amounts ) | 2026 | 2025 | 2026 | 2025 | ||||
Numerator: | ||||||||
Net income attributable to equity holders of Constellium SE | ||||||||
Denominator: | ||||||||
Basic - weighted-average ordinary shares outstanding | ||||||||
Dilutive effect of non-vested restricted stock units and performance-based restricted stock units | ||||||||
Diluted - weighted-average ordinary shares, of restricted stock units and performance-based restricted stock units | ||||||||
Basic earnings per share | $ | $ | $ | $ | ||||
Diluted earnings per share | $ | $ | $ | $ | ||||
At September 30, 2026 | At December 31, 2025 | |||
(in millions of U.S. dollars) | Current | Current | ||
Trade receivables - gross | ||||
Allowance for credit losses | ( | ( | ||
Total trade receivables - net | ||||
Total other receivables | ||||
Total trade receivables and other |
(in millions of U.S. dollars) | At September 30, 2026 | At December 31, 2025 | ||
Finished goods | ||||
Work in progress | ||||
Raw materials | ||||
Stores and supplies | ||||
Total inventories |
At September 30, 2026 | At December 31, 2025 | |||
(in millions of U.S. dollars) | Current | Current | ||
Trade payables | ||||
Employees' entitlements | ||||
Other payables | ||||
Total other | ||||
Total trade payables and other |
Nine months ended September 30, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Contract liabilities and other liabilities to customers at January 1, | ||||
Revenue deferred to contract liabilities | ||||
Revenue recognized from contract liabilities | ( | ( | ||
Effect of changes in foreign currency rates and other changes | ( | |||
Contract liabilities and other liabilities to customers at September 30, | ||||
At September 30, 2026 | At December 31, 2025 | |||||||||
(in millions of U.S. dollars) | Nominal Value in Currency | Nominal rate | Effective rate | Face Value | Debt issuance costs | Accrued interest | Carrying value | Carrying value | ||
Secured Pan-U.S. ABL (due 2029) | $ | Floating | ||||||||
Senior Unsecured Notes | ||||||||||
Issued June 2020 and due 2028 (A) | $ | ( | ||||||||
Issued February 2021 and due 2029 | $ | ( | ||||||||
Issued June 2021 and due 2029 | € | ( | ||||||||
Issued August 2024 and due 2032 | $ | ( | ||||||||
Issued August 2024 and due 2032 | € | ( | ||||||||
Finance lease liabilities | ||||||||||
Other loans | ||||||||||
Total debt | ( | |||||||||
Of which non-current | ||||||||||
Of which current (B) | ||||||||||
At September 30, 2026 | At December 31, 2025 | |||||||||||
(in millions of U.S. dollars) | Non- current | Current | Total | Non- current | Current | Total | ||||||
Derivatives that qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Derivatives that do not qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Currency net debt derivatives | ||||||||||||
Energy derivatives | ||||||||||||
Metal derivatives | ||||||||||||
Fair value of derivative instruments - assets | ||||||||||||
Derivatives that qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Derivatives that do not qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Energy derivatives | ||||||||||||
Metal derivatives | ||||||||||||
Fair value of derivative instruments - liabilities | ||||||||||||
At September 30, 2026 | At December 31, 2025 | |||||||||||||||
(in millions of U.S. dollars) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||
Fair value of derivative instruments - assets | ||||||||||||||||
Fair value of derivative instruments - liabilities | ||||||||||||||||
Sold currencies | Maturity Year | Less than 1 year | Over 1 year | |||
USD | 2026-2031 | |||||
CHF | 2026-2031 | |||||
CZK | 2026 | |||||
Other currencies | 2026-2027 |
Purchased currencies | ||||||
USD | 2026-2028 | |||||
CHF | 2026-2030 | |||||
CZK | 2026-2028 | |||||
Other currencies | 2027 |
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Derivatives that do not qualify for hedge accounting | ||||||||
Included in Other gains and losses - net | ||||||||
Realized (losses) / gains on foreign currency derivatives - net (A) | ( | ( | ||||||
Unrealized (losses) / gains on foreign currency derivatives - net (B) | ( | ( | ( | |||||
Derivatives that qualify for hedge accounting | ||||||||
Included in Other comprehensive income | ||||||||
Unrealized (losses) / gains on foreign currency derivatives - net | ( | ( | ( | |||||
(Losses) / gains reclassified from cash flow hedge reserve to the Consolidated Income Statement | ( | ( | ( | |||||
Included in Revenue (C) | ||||||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||||||
Unrealized (losses) / gains on foreign currency derivatives - net | ( | |||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Derivatives that do not qualify for hedge accounting | ||||||||
Included in Finance costs - net | ||||||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||||||
Unrealized gains / (losses) on foreign currency derivatives - net | ( | |||||||
Total | ( | |||||||
(in millions of U.S. dollars) | Maturity Year | Less than 1 year | Over 1 year | |||
Metal | 2026-2028 | |||||
Natural gas | 2026-2029 |
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollar) | 2026 | 2025 | 2026 | 2025 | ||||
Derivatives that do not qualify for hedge accounting | ||||||||
Included in Other gains and losses - net | ||||||||
Realized gains / (losses) on commodities derivatives - net (A) | ( | |||||||
Unrealized gains / (losses) on commodities derivatives - net | ( | |||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||
(in millions of U.S. dollars) | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | |||||
Current service cost | ( | ( | ( | ( | ( | ( | ( | ( | |||||
Interest cost | ( | ( | ( | ( | ( | ( | ( | ( | |||||
Expected return on plan assets | |||||||||||||
Immediate recognition of losses arising over the year | ( | ||||||||||||
Amortization of past service gain | |||||||||||||
Amortization of net actuarial gain | |||||||||||||
Curtailment and settlements | ( | ( | |||||||||||
Total net pension and other long- term benefit cost | ( | ( | ( | ( | ( | ||||||||
At September 30, 2026 | At December 31, 2025 | |||||||
(in millions of U.S. dollars) | Current | Non-current | Current | Non-current | ||||
Close down and environmental remediation costs | ||||||||
Restructuring costs | ||||||||
Legal claims and other costs | ||||||||
Total provisions | ||||||||
Three months ended September 30, 2026 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At June 30, 2026 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ||||||
At September 30, 2026 | ( | ( | ||||||
Three months ended September 30, 2025 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At June 30, 2025 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
At September 30, 2025 | ( | |||||||
Nine months ended September 30, 2026 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At January 1, 2026 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | ( | ||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to retained earnings | ||||||||
At September 30, 2026 | ( | ( | ||||||
Nine months ended September 30, 2025 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At January 1, 2025 | ( | ( | ( | |||||
Other comprehensive income / (loss) before reclassification | ||||||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to retained earnings | ||||||||
At September 30, 2025 | ( | |||||||
2026 PSUs | ||
Fair value at grant date (in U.S. dollars) | ||
Share price at grant date (in U.S. dollars) | ||
Dividend yield | ||
Expected volatility (A) | ||
Risk-free interest rate (U.S. government bond yield) |
Three months ended September 30, 2026 | Nine months ended September 30, 2026 | |||||||
(as a % of total) | Revenue | Segment Adjusted EBITDA | Revenue | Segment Adjusted EBITDA | ||||
A&T | 25% | 36% | 25% | 40% | ||||
P&ARP | 62% | 58% | 61% | 56% | ||||
AS&I | 15% | 8% | 16% | 8% | ||||
H&C (1) | —% | (2)% | —% | (4)% | ||||
Total | 100% | 100% | 100% | 100% | ||||
Three months ended September 30, | Nine months ended September 30, | Percent changes QTD | Percent changes YTD | |||||||||
(U.S. dollars per ton) | 2026 | 2025 | 2026 | 2025 | 2026 vs 2025 | 2026 vs 2025 | ||||||
Average LME transaction price | 3,226 | 2,618 | 3,328 | 2,566 | 23% | 30% | ||||||
Average Midwest premium | 2,418 | 1,566 | 2,409 | 1,095 | 54% | 120% | ||||||
Average all-in aluminum price U.S. | 5,644 | 4,184 | 5,737 | 3,661 | 35% | 57% | ||||||
Average LME transaction price | 3,226 | 2,618 | 3,328 | 2,566 | 23% | 30% | ||||||
Average Rotterdam premium | 510 | 212 | 494 | 233 | 141% | 112% | ||||||
Average all-in aluminum price Europe | 3,736 | 2,830 | 3,822 | 2,799 | 32% | 37% | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
Revenue | 2,639 | 100% | 2,166 | 100% | 7,848 | 100% | 6,248 | 100% | ||||||||
Cost of sales (excluding depreciation and amortization) | (2,272) | 86% | (1,852) | 86% | (6,581) | 84% | (5,408) | 87% | ||||||||
Depreciation and amortization | (82) | 3% | (84) | 4% | (249) | 3% | (244) | 4% | ||||||||
Selling and administrative expenses | (84) | 3% | (85) | 4% | (282) | 4% | (251) | 4% | ||||||||
Research and development expenses | (12) | —% | (12) | 1% | (39) | —% | (37) | 1% | ||||||||
Other gains and losses – net | (2) | —% | 20 | 1% | 32 | —% | 19 | —% | ||||||||
Finance costs – net | (27) | 1% | (27) | 1% | (83) | 1% | (83) | 1% | ||||||||
Income before tax | 160 | 6% | 126 | 6% | 646 | 8% | 244 | 4% | ||||||||
Income tax expense | (41) | 2% | (38) | 2% | (183) | 2% | (82) | 1% | ||||||||
Net income | 119 | 5% | 88 | 4% | 463 | 6% | 162 | 3% | ||||||||
Shipment volumes (in kt) | 368 | n/a | 373 | n/a | 1,120 | n/a | 1,130 | n/a | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Realized (losses) / gains on foreign currency derivatives - net | (3) | 6 | (3) | 6 | ||||
Realized gains / (losses) on commodities derivatives - net | — | 4 | 104 | (15) | ||||
Realized (losses) / gains on derivatives | (3) | 10 | 101 | (9) | ||||
Unrealized (losses) / gains on foreign currency derivatives - net | (5) | (6) | (19) | 32 | ||||
Unrealized gains / (losses) on commodities derivatives - net | 10 | 19 | (36) | 2 | ||||
Unrealized gains / (losses) on derivatives at fair value through profit and loss - net | 5 | 13 | (55) | 34 | ||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
A&T | 664 | 25% | 481 | 22% | 1,954 | 25% | 1,441 | 23% | ||||||||
P&ARP | 1,625 | 62% | 1,307 | 60% | 4,782 | 61% | 3,729 | 60% | ||||||||
AS&I | 402 | 15% | 409 | 19% | 1,275 | 16% | 1,211 | 19% | ||||||||
H&C (1) | 2 | —% | 1 | —% | 6 | —% | 3 | —% | ||||||||
Inter-segment eliminations | (55) | n.m | (32) | n.m | (169) | n.m | (136) | n.m | ||||||||
Total revenue | 2,639 | 100% | 2,166 | 100% | 7,848 | 100% | 6,248 | 100% | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in kt and as a % of shipments) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
A&T | 59 | 16% | 50 | 13% | 184 | 16% | 154 | 14% | ||||||||
P&ARP | 266 | 72% | 275 | 74% | 793 | 71% | 820 | 73% | ||||||||
AS&I | 46 | 13% | 48 | 13% | 151 | 14% | 155 | 14% | ||||||||
Inter-segment eliminations | (3) | n.m | — | n.m | (9) | n.m | (1) | n.m | ||||||||
Total shipments | 368 | 100% | 373 | 100% | 1,120 | 100% | 1,130 | 100% | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
A&T | 102 | 15% | 90 | 19% | 340 | 17% | 256 | 18% | ||||||||
P&ARP | 162 | 10% | 82 | 6% | 478 | 10% | 217 | 6% | ||||||||
AS&I | 21 | 5% | 33 | 8% | 71 | 6% | 67 | 6% | ||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | |||
Segment Adjusted EBITDA for the three months ended September 30, 2025 | 90 | 82 | 33 | |||
Volume | 34 | (7) | (6) | |||
Price and product mix | 20 | 18 | (23) | |||
Costs | (40) | 70 | 18 | |||
Foreign exchange and other | (2) | (1) | (1) | |||
Segment Adjusted EBITDA for the three months ended September 30, 2026 | 102 | 162 | 21 | |||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | |||
Segment Adjusted EBITDA for the nine months ended September 30, 2025 | 256 | 217 | 67 | |||
Volume | 106 | (18) | (10) | |||
Price and product mix | 35 | 64 | (31) | |||
Costs | (64) | 208 | 42 | |||
Foreign exchange and other | 7 | 7 | 3 | |||
Segment Adjusted EBITDA for the nine months ended September 30, 2026 | 340 | 478 | 71 |
Nine months ended September 30, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Net Cash Flows from / (used in) | ||||
Operating activities | 420 | 271 | ||
Investing activities | (195) | (200) | ||
Financing activities | (184) | (103) | ||
Net increase / (decrease) in cash and cash equivalents, excluding the effect of exchange rate changes | 41 | (32) | ||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Net income | 119 | 88 | 463 | 162 | ||||
Income tax expense | 41 | 38 | 183 | 82 | ||||
Finance costs – net | 27 | 27 | 83 | 83 | ||||
Expenses on factoring arrangements | 6 | 5 | 15 | 16 | ||||
Depreciation and amortization | 82 | 84 | 249 | 244 | ||||
Impairment of assets | — | — | 3 | — | ||||
Restructuring costs | — | 1 | 5 | 3 | ||||
Unrealized gains / (losses) on derivatives | (5) | (13) | 55 | (34) | ||||
Unrealized exchange gains from the remeasurement of monetary assets and liabilities – net | — | (1) | (1) | (1) | ||||
Pension and other post-employment benefits - non- operating gains | (3) | (3) | (10) | (10) | ||||
Share based compensation | 8 | 7 | 27 | 20 | ||||
Losses on disposal | — | — | 1 | 1 | ||||
Other (A) | 1 | 2 | 1 | — | ||||
Adjusted EBITDA1 | 276 | 235 | 1,074 | 566 | ||||
of which Metal price lag (B) | (4) | 39 | 222 | 59 | ||||
Period | Total number of shares purchased | Average price paid per share (in U.S. dollars) | Total number of shares purchased as part of publicly announced plans or programs(1) | Maximum approximate dollar value of shares that may yet be purchased under the program(2) | ||||
July 1 - July 31, 2026 | 515,106 | 29.12 | 515,106 | 272,000,049 | ||||
August 1 - August 31, 2026 | 529,335 | 28.34 | 529,335 | 257,000,065 | ||||
September 1 - September 30, 2026 | — | — | — | 257,000,065 | ||||
Total | 1,044,441 | 1,044,441 | 257,000,065 |
Exhibit | Description |
3.1 | |
10.1 | |
31.1 | |
31.2 | |
32.1 | |
32.2 | |
101.INS | Inline XBRL Instance Document** |
101.SCH | Inline XBRL Taxonomy Extension Schema Document** |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document** |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document** |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document** |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document** |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)** |
Constellium SE | |||
Date: | October 28, 2026 | By: | /s/ Ingrid Joerg |
Name: Ingrid Joerg | |||
Title: Chief Executive Officer and Director | |||
Date: | October 28, 2026 | By: | /s/ Jack Guo |
Name: Jack Guo | |||
Title: Executive Vice President & Chief Financial Officer |